Information Provided By: 
Fly News Breaks for March 28, 2017
TSRO
Mar 28, 2017 | 07:26 EDT
After Tesaro's niraparib was approved as a maintenance therapy for recurrent ovarian cancer, Wells Fargo says that the broad label granted to the drug and its potential use in multiple lines of therapy should enable Tesaro's results to beat its previous estimates. Wells thinks that PARP inhibitors could become a $10B+ category, and it says that niraparib is "a best-in-class PARP." Wells keeps an Outperform rating on the stock.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
